A new gene-delivery vehicle could make gene therapy for muscle diseases safer and more effective
Researchers have engineered a gene-shuttling virus used in gene therapy to better target muscle tissue at lower doses.

Credit: Allison Dougherty, Broad Communications
Sharif Tabebordbar led the team of researchers that developed MyoAAV, a new family of viral vectors that that could lead to safer gene therapies for genetic muscle disease